200,000+ products from a single source!
sales@angenechem.com
14611-52-0 | Benzeneethanamine, N,α-dimethyl-N-2-propyn-1-yl-, hydrochloride (1:1), (αR)-
CAS No: 14611-52-0 Catalog No: AG001DPB MDL No:MFCD00055150
Product Description
Catalog Number:
AG001DPB
Chemical Name:
Benzeneethanamine, N,α-dimethyl-N-2-propyn-1-yl-, hydrochloride (1:1), (αR)-
CAS Number:
14611-52-0
Molecular Formula:
C13H18ClN
Molecular Weight:
223.7417
MDL Number:
MFCD00055150
IUPAC Name:
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;hydrochloride
InChI:
InChI=1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1
InChI Key:
IYETZZCWLLUHIJ-UTONKHPSSA-N
SMILES:
C[C@@H](N(CC#C)C)Cc1ccccc1.Cl
UNII:
6W731X367Q
Properties
Complexity:
195
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
1
Defined Bond Stereocenter Count:
0
Exact Mass:
223.113g/mol
Formal Charge:
0
Heavy Atom Count:
15
Hydrogen Bond Acceptor Count:
1
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
223.744g/mol
Monoisotopic Mass:
223.113g/mol
Rotatable Bond Count:
4
Topological Polar Surface Area:
3.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Inhibition of monoamine oxidase-B by selegiline reduces cigarette smoke-induced oxidative stress and inflammation in airway epithelial cells. | Toxicology letters 20170215 |
| Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. | Chemico-biological interactions 20150325 |
| Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor. | Journal of neural transmission (Vienna, Austria : 1996) 20150201 |
| Deprenyl enhances the teratogenicity of hydroxyurea in organogenesis stage mouse embryos. | Toxicological sciences : an official journal of the Society of Toxicology 20130801 |
| Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro. | International journal of pharmaceutics 20121115 |
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neuroblastic apoptosis in the subventricular zone is caused by 1-methy-4-phenylpiridinium (MPP(+)) converted from MPTP through MAO-B. | Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20121101 |
| Retention rate of selegiline in early Parkinson's disease: a retrospective survey. | International journal of clinical practice 20121001 |
| Involvement of monoamine oxidase B on models of postoperative and neuropathic pain in mice. | European journal of pharmacology 20120905 |
| Cerebral blood flow and freezing of gait in Parkinson's disease. | Acta neurologica Scandinavica 20120901 |
| Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease. | Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20120901 |
| Modulations of brain amines and dopaminergic behavior by a novel, reversible and selective MAO-B inhibitor. | Brain research 20120827 |
| Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. | British journal of clinical pharmacology 20120801 |
| Activity-based probes for studying the activity of flavin-dependent oxidases and for the protein target profiling of monoamine oxidase inhibitors. | Angewandte Chemie (International ed. in English) 20120709 |
| AIRE-induced apoptosis is associated with nuclear translocation of stress sensor protein GAPDH. | Biochemical and biophysical research communications 20120622 |
| Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease. | Neurology 20120612 |
| Cerebral ischemia-reperfusion induces GAPDH S-nitrosylation and nuclear translocation. | Biochemistry. Biokhimiia 20120601 |
| Cardiovascular baroreceptor activity and selective inhibition of monoamine oxidase. | European journal of pharmacology 20120515 |
| Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes. | Journal of neural transmission (Vienna, Austria : 1996) 20120501 |
| Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures. | The Journal of clinical psychiatry 20120501 |
| Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. | Journal of neural transmission (Vienna, Austria : 1996) 20120401 |
| In vitro-in vivo correlation for intrinsic clearance for CP-409,092 and sumatriptan: a case study to predict the in vivo clearance for compounds metabolized by monoamine oxidase. | Xenobiotica; the fate of foreign compounds in biological systems 20120401 |
| In vivo evaluation in cynomolgus monkey brain and metabolism of [¹⁸F]fluorodeprenyl: a new MAO-B pet radioligand. | Synapse (New York, N.Y.) 20120401 |
| 8-Substituted 3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation, and docking studies. | ChemMedChem 20120305 |
| Selegiline transdermal system (STS) as an aid for smoking cessation. | Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 20120301 |
| Induction of adipose-derived stem cell into motoneuron-like cells using selegiline as preinducer. | Brain research 20120227 |
| Tyrosine hydroxylase deficiency in Taiwanese infants. | Pediatric neurology 20120201 |
| The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model. | Journal of neural transmission (Vienna, Austria : 1996) 20120101 |
| Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20120101 |
| Selegiline: a reappraisal of its role in Parkinson disease. | Clinical neuropharmacology 20120101 |
| Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk. | Toxicology 20111218 |
| In vivo imaging of astrocytosis in Alzheimer's disease: an ¹¹C-L-deuteriodeprenyl and PIB PET study. | European journal of nuclear medicine and molecular imaging 20111201 |
| PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Experimental neurology 20111201 |
| Predicting successful 24-hr quit attempt in a smoking cessation intervention. | Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 20111101 |
| Pharmacoresistant convulsions and visual hallucinations around two weeks after selegiline overdose: a case report. | Pharmacopsychiatry 20111101 |
| Synthesis of three novel fluorine-18 labeled analogues of L-deprenyl for positron emission tomography (PET) studies of monoamine oxidase B (MAO-B). | Journal of medicinal chemistry 20111027 |
| Trans-differentiation of the adipose tissue-derived stem cells into neuron-like cells expressing neurotrophins by selegiline. | Iranian biomedical journal 20111001 |
| Selegiline-functionalized, PEGylated poly(alkyl cyanoacrylate) nanoparticles: Investigation of interaction with amyloid-β peptide and surface reorganization. | International journal of pharmaceutics 20110920 |
| Effects of selegiline, a monoamine oxidase B inhibitor, on differentiation of P19 embryonal carcinoma stem cells, into neuron-like cells. | In vitro cellular & developmental biology. Animal 20110901 |
| Transdermal delivery of selegiline from alginate-Pluronic composite thermogels. | International journal of pharmaceutics 20110830 |
| CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. | Brain research 20110823 |
| Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20110801 |
| MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins. | Bioorganic & medicinal chemistry letters 20110715 |
| The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment. | Acta neurologica Scandinavica 20110701 |
| Differences in smoking expectancies in smokers with and without a history of major depression. | Addictive behaviors 20110401 |
| Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times. | Parkinsonism & related disorders 20110301 |
| Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency. | Journal of child neurology 20110201 |
| Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease. | Parkinsonism & related disorders 20110201 |
| MAO inhibitors. | Cleveland Clinic journal of medicine 20110201 |
| The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species. | Journal of molecular biology 20110107 |
| Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. | Neurochemistry international 20110101 |
| Selegiline and rasagiline: twins or distant cousins? | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20110101 |
| Pharmacotherapy for late-life depression. | The Journal of clinical psychiatry 20110101 |
| Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. | BMC pharmacology 20110101 |
| Elevated [11C]-D-deprenyl uptake in chronic Whiplash Associated Disorder suggests persistent musculoskeletal inflammation. | PloS one 20110101 |
| Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. | PloS one 20110101 |
| The pharmacology of selegiline. | International review of neurobiology 20110101 |
| Selective inhibitors of monoamine oxidase type B and the 'cheese effect'. | International review of neurobiology 20110101 |
| Supplementation of deprenyl attenuates age associated alterations in rat cerebellum. | Molecular biology reports 20101201 |
| Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. | Journal of clinical pharmacology 20101201 |
| R-deprenyl: pharmacological spectrum of its activity. | Neurochemical research 20101201 |
| MAO inhibitors: risks, benefits, and lore. | Cleveland Clinic journal of medicine 20101201 |
| Ring opening of pymisyl-protected aziridines with organocuprates. | Chemistry (Weinheim an der Bergstrasse, Germany) 20101102 |
| Transdermal iontophoretic delivery of selegiline hydrochloride, in vitro. | Journal of drug targeting 20101101 |
| Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. | Progress in neurobiology 20101101 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| Orthostatic hypotension: a non-motor complication assessment in 82 patients with idiopathic Parkinson's disease in Phramongkutklao Hospital. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20101101 |
| The fabulous neuroprotection of selegiline: memoir and prospectus. | Journal of child neurology 20101001 |
| Clozapine for medication-related pathological gambling in Parkinson disease. | Movement disorders : official journal of the Movement Disorder Society 20100915 |
| Age-related protective effect of deprenyl on changes in the levels of diagnostic marker enzymes and antioxidant defense enzymes activities in cerebellar tissue in Wistar rats. | Cell stress & chaperones 20100901 |
| HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20100901 |
| Changes in smoking expectancies in abstinent, reducing, and non-abstinent participants during a pharmacological trial for smoking cessation. | Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 20100901 |
| Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. | Addiction (Abingdon, England) 20100901 |
| [The feasibility of synthetic enhancer substances for preventive nanotherapy]. | Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20100901 |
| Slowing the decline. | Nature 20100826 |
| Cytoprotective effect of (-)-deprenyl, (-)desmethyl-deprenyl and (-)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells. | Journal of neural transmission (Vienna, Austria : 1996) 20100601 |
| A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. | Biological psychiatry 20100501 |
| Marked improvement in Segawa syndrome after L-dopa and selegiline treatment. | Pediatric neurology 20100501 |
| [General anaesthesia for neurological diseases]. | Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS 20100501 |
| Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo. | Cellular and molecular neurobiology 20100401 |
| Manganese neurotoxic time course is not influenced by L-deprenyl systemic treatment: influence of L-deprenyl in manganese neurotoxic time course. | Brain research 20100304 |
| Selegiline is an efficient and potent inducer for bone marrow stromal cell differentiation into neuronal phenotype. | Neurological research 20100301 |
| A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. | Drug and alcohol dependence 20100301 |
| [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease]. | Fortschritte der Neurologie-Psychiatrie 20100301 |
| Cognitive aspects of congenital learned helplessness and its reversal by the monoamine oxidase (MAO)-B inhibitor deprenyl. | Neurobiology of learning and memory 20100201 |
| (-)-Deprenyl inhibits vascular hyperpermeability after hemorrhagic shock. | Shock (Augusta, Ga.) 20100101 |
| Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. | Clinical neuropharmacology 20100101 |
| Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease. | Clinical neuropharmacology 20100101 |
| Frontotemporal dementia and pharmacologic interventions. | The Journal of neuropsychiatry and clinical neurosciences 20100101 |
| Transdermal selegiline in patients receiving electroconvulsive therapy. | Psychosomatics 20100101 |
| Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat. | Neuropsychobiology 20100101 |
| Zonisamide attenuates MPTP neurotoxicity in marmosets. | Journal of pharmacological sciences 20100101 |
| A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. | Movement disorders : official journal of the Movement Disorder Society 20091215 |
| Selegiline and oxidative stress in HIV-associated cognitive impairment. | Neurology 20091208 |
| Acidic vesicles of the endo-exocytic pathways as targets for some anti-monoamine oxidase drugs. | Metabolic brain disease 20091201 |
| [Severe apathy following head injury: improvement with Selegiline treatment]. | Neuro-Chirurgie 20091201 |
| [Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal]. | Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20091201 |
| Effect of deprenyl on free radical oxidation in rat brain during immobilization stress. | Bulletin of experimental biology and medicine 20091201 |
| Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. | Neurology 20091103 |
| Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain. | Journal of neural transmission (Vienna, Austria : 1996) 20091101 |
| Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. | The Cochrane database of systematic reviews 20091007 |
| Transdermal permeation of selegiline from hydrogel-membrane drug delivery systems. | International journal of pharmaceutics 20091001 |
| (-)Deprenyl-N-oxide, a (-)deprenyl metabolite, is cytoprotective after hypoxic injury in PC12 cells, or after transient brain ischemia in gerbils. | Journal of the neurological sciences 20090815 |
| Serotonin toxicity caused by moclobemide too soon after paroxetine-selegiline. | Journal of the Chinese Medical Association : JCMA 20090801 |
| Selegiline shortage: Causes and costs of a generic drug shortage. | Neurology 20090721 |
| Selegiline transdermal system: a novel treatment option for major depressive disorder. | Expert opinion on pharmacotherapy 20090701 |
| A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors. | Bioorganic & medicinal chemistry letters 20090615 |
| Teasing apart drug treatments and individual symptoms in narcolepsy. | Sleep medicine 20090601 |
| Short-term erythrosine B-induced inhibition of the brain regional serotonergic activity suppresses motor activity (exploratory behavior) of young adult mammals. | Pharmacology, biochemistry, and behavior 20090601 |
| Involvement of protein trafficking in deprenyl-induced alpha-secretase activity regulation in PC12 cells. | European journal of pharmacology 20090521 |
| Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. | The international journal of neuropsychopharmacology 20090501 |
| Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. | Clinical pharmacology and therapeutics 20090501 |
| Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. | Journal of pharmacological sciences 20090501 |
| MAO-B inhibitor know-how: back to the pharm. | Neurology 20090414 |
| Hyperserotonergic phenotype after monoamine oxidase inhibition in larval zebrafish. | Journal of neurochemistry 20090401 |
| Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. | Neurotoxicity research 20090401 |
| 'Bad guys' among the antiparkinsonian drugs. | Psychiatria Danubina 20090301 |
| Antioxidant and antiapoptotic activities of deprenyl and estradiol co-administration in aged rat kidney. | Acta biologica Hungarica 20090301 |
| Neuroprotection by rasagiline in thiamine deficient rats. | Brain research 20090223 |
| MPTP and MPP+ target specific aminergic cell populations in larval zebrafish. | Journal of neurochemistry 20090201 |
| [Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings]. | Ideggyogyaszati szemle 20090130 |
| A case report of high-dose transdermal selegiline in the treatment of major depressive disorder. | Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20090101 |
| Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits. | European review for medical and pharmacological sciences 20090101 |
| A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion. | BMC clinical pharmacology 20090101 |
| (-)-Deprenyl inhibits thermal injury-induced apoptotic signaling and hyperpermeability in microvascular endothelial cells. | Journal of burn care & research : official publication of the American Burn Association 20090101 |
| Serum prolactin as a tool for the follow-up of treated DHPR-deficient patients. | Journal of inherited metabolic disease 20081201 |
| Antidepressant activity of curcumin: involvement of serotonin and dopamine system. | Psychopharmacology 20081201 |
| 1-Methyl-4-phenyl-pyridinium ion-induced oxidative stress, c-Jun phosphorylation and DNA fragmentation factor-45 cleavage in SK-N-SH cells are averted by selegiline. | Neurochemistry international 20081201 |
| The effect of short-term administration of (-)-deprenyl and isatin on the expressions of some genes in the mouse brain cortex. | Medical science monitor : international medical journal of experimental and clinical research 20081201 |
| Neural progenitor cells are protected against MPTP by MAO-B inhibitors. | Neurotoxicology 20081101 |
| Orally disintegrating selegiline for the treatment of Parkinson's disease. | Expert opinion on pharmacotherapy 20081101 |
| Protective effects of deprenyl in transient cerebral ischemia in rats. | The Chinese journal of physiology 20081031 |
| Apomorphine offers new insight into dopaminergic neuron vulnerability in mesencephalic cultures. | Neuropharmacology 20081001 |
| Pharmacological treatment in moderate-to-severe Alzheimer's disease. | Expert opinion on pharmacotherapy 20081001 |
| Detection of levorotatory methamphetamine and levorotatory amphetamine in urine after ingestion of an overdose of selegiline. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20081001 |
| [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. | Fortschritte der Neurologie-Psychiatrie 20081001 |
| [Motor symptoms in Parkinson disease]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20080925 |
| Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. | Neurology 20080812 |
| Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). | Behavioural brain research 20080719 |
| Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. | Journal of neurochemistry 20080601 |
| Study of high deprenyl dose on the preimplantation embryo development and lymphocyte DNA in rat. | General physiology and biophysics 20080601 |
| Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells. | Neurological research 20080501 |
| The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. | British journal of pharmacology 20080501 |
| Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. | Movement disorders : official journal of the Movement Disorder Society 20080415 |
| Selegilin exerts antidepressant-like effects during the forced swim test in adrenocorticotropic hormone-treated rats. | Journal of pharmacological sciences 20080401 |
| Optimization and validation of a dissolution test for selegiline hydrochloride tablets by a novel rapid HPLC assay using a monolithic stationary phase. | Journal of pharmaceutical and biomedical analysis 20080313 |
| Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. | Human psychopharmacology 20080301 |
| Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. | The Journal of pharmacology and experimental therapeutics 20080301 |
| Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production. | Neurotoxicology 20080301 |
| [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508]. | Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20080301 |
| [Role of apoptosis in the kidney after reperfusion]. | Orvosi hetilap 20080217 |
| Transdermal selegiline: new opportunity for managing depression. | The Journal of the American Osteopathic Association 20080201 |
| [The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life]. | Ideggyogyaszati szemle 20080130 |
| Parallel analysis of stimulants in saliva and urine by gas chromatography/mass spectrometry: perspectives for 'in competition' anti-doping analysis. | Analytica chimica acta 20080114 |
| The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. | Journal of affective disorders 20080101 |
| Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline. | Journal of neural transmission (Vienna, Austria : 1996) 20080101 |
| Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets. | Psychopharmacology 20080101 |
| Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic. | Journal of psychiatric practice 20080101 |
| Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant. | Arzneimittel-Forschung 20080101 |
| Paradoxical effects of adenosine receptor ligands on hydroxyl radical generation by L-DOPA in the rat striatum. | Pharmacological reports : PR 20080101 |
| Antagonistic effect of low deprenyl dose on the preimplantation embryo development in rat. | Bratislavske lekarske listy 20080101 |
| Possible new antiaging strategies related to neuroendocrine-immune interactions. | Neuroimmunomodulation 20080101 |
| Differential effects of selegiline on glucose synthesis in rabbit kidney-cortex tubules and hepatocytes. In vitro and in vivo studies. | Chemico-biological interactions 20071215 |
| In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. | Drug metabolism and disposition: the biological fate of chemicals 20071201 |
| Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. | Pharmacotherapy 20071201 |
| Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale. | The Journal of clinical psychiatry 20071201 |
| Deprenyl treatment attenuates long-term pre- and post-synaptic changes evoked by chronic methamphetamine. | European journal of pharmacology 20071114 |
| Gestational exposure to nicotine and monoamine oxidase inhibitors influences cocaine-induced locomotion in adolescent rats. | Psychopharmacology 20071101 |
| Bystander effects of ionizing radiation can be modulated by signaling amines. | Environmental research 20071001 |
| Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. | Journal of clinical pharmacology 20071001 |
| Zydis selegiline in the management of Parkinson's disease. | Expert opinion on pharmacotherapy 20071001 |
| A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. | Neurology 20070925 |
| Lost in translation: again, another failed neuroprotection trial. | Neurology 20070925 |
| Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? | Journal of psychiatry & neuroscience : JPN 20070901 |
| Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. | Clinical therapeutics 20070901 |
| A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl. | Journal of neuroscience methods 20070815 |
| Selegiline transdermal system: current awareness and promise. | Progress in neuro-psychopharmacology & biological psychiatry 20070815 |
| Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers. | Journal of clinical pharmacology 20070801 |
| Low plasma uric acid level in Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20070615 |
| The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. | Molecular pharmacology 20070601 |
| Antioxidant effects of selegiline in oxidative stress induced by iron neonatal treatment in rats. | Neurochemical research 20070601 |
| Therapeutic advances in narcolepsy. | Sleep medicine 20070601 |
| Treatment-resistant depression: response to low-dose transdermal but not oral selegiline. | Journal of clinical psychopharmacology 20070601 |
| Transdermal selegiline. | Drugs of today (Barcelona, Spain : 1998) 20070601 |
| Rasagiline as a therapy for Parkinson's disease (PD). | The American journal of geriatric pharmacotherapy 20070601 |
| Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro. | Journal of neuroscience research 20070515 |
| The role of selegiline in the treatment of negative symptoms associated with schizophrenia. | The Annals of pharmacotherapy 20070501 |
| Bacopa monniera prevents from aluminium neurotoxicity in the cerebral cortex of rat brain. | Journal of ethnopharmacology 20070420 |
| Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. | Journal of the neurological sciences 20070415 |
| Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. | Current medical research and opinion 20070401 |
| Translating the evidence on atypical depression into clinical practice. | The Journal of clinical psychiatry 20070401 |
| P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. | Drug metabolism and pharmacokinetics 20070401 |
| Involvement of cytochromes P450 2D6, 2B6 and 2C19 in the metabolism of (-)-deprenyl and N-methyl,N-propargylphenylethylamine. | Drug metabolism letters 20070401 |
| Oxygen-glucose deprivation-induced changes in organotypic cultures of the rat hippocampus. | Ideggyogyaszati szemle 20070330 |
| Metabolism of N-methyl, N-propargylphenylethylamine: studies with human liver microsomes and cDNA expressed cytochrome P450 (CYP) enzymes. | Cellular and molecular neurobiology 20070301 |
| Selegiline and blood pressure in patients with Parkinson's disease. | Acta neurologica Scandinavica 20070201 |
| Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications. | Journal of clinical pharmacology 20070201 |
| Antioxidants and Alzheimer's disease: time to stop feeding vitamin E to dementia patients? | International psychogeriatrics 20070201 |
| Separation of enantiomers of deprenyl with various CDs in CE and the effect of enantiomer migration order on enantiomeric impurity determination of selegiline in active ingredients and tablets. | Electrophoresis 20070201 |
| Psychopharmacology column: why choose selegiline transdermal system for refractory depression? | Issues in mental health nursing 20070201 |
| Management of sexual dysfunction due to antipsychotic drug therapy. | The Cochrane database of systematic reviews 20070124 |
| Improvement of mouse brain mitochondrial function after deprenyl treatment. | Neuroscience 20070119 |
| Mitogen activated protein kinase and protein kinase C activation mediate promotion of sAPPalpha secretion by deprenyl. | Neurochemistry international 20070101 |
| Chronic (-)-deprenyl administration attenuates dendritic developmental impairment induced by early social isolation in the rat. | Developmental neuroscience 20070101 |
| Seligiline transdermal system in depression. | Expert opinion on pharmacotherapy 20070101 |
| Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour. | CNS spectrums 20070101 |
| Selegiline transdermal system: in the treatment of major depressive disorder. | Drugs 20070101 |
| The effect of l-deprenyl on tissue mRNA expressions of NOS isoforms and NO levels in an experimental diabetes mellitus model. | Journal of neural transmission (Vienna, Austria : 1996) 20070101 |
| Selegiline transdermal system in major depressive disorder: profile report. | CNS drugs 20070101 |
| Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. | Clinical neuropharmacology 20070101 |
| Suppression of apoptosis and oxidative stress by deprenyl and estradiol in aged rat liver. | Acta histochemica 20070101 |
| Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors. | Drugs & aging 20070101 |
| Selegiline orally disintegrating tablets in patients with Parkinson disease and 'wearing off' symptoms. | Clinical neuropharmacology 20070101 |
| Placebo response in Parkinson trials using patient diaries: sites do matter. | Clinical neuropharmacology 20070101 |
| A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition. | Clinical neuropharmacology 20070101 |
| Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. | Journal of neural transmission. Supplementum 20070101 |
| Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. | Journal of neural transmission. Supplementum 20070101 |
| Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. | Psychopharmacology bulletin 20070101 |
| Commentary on the treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. | Psychopharmacology bulletin 20070101 |
| Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. | HIV clinical trials 20070101 |
| Simultaneous determination of selegiline and desmethylselegiline in human body fluids by headspace solid-phase microextraction and gas chromatography-mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061205 |
| Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. | Drug and alcohol dependence 20061201 |
| Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. | Journal of clinical psychopharmacology 20061201 |
| L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action. | Pharmacology, biochemistry, and behavior 20061201 |
| The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. | Current Alzheimer research 20061201 |
| Monoamine oxidase inhibitory coumarins from the aerial parts of Dictamnus albus. | Archives of pharmacal research 20061201 |
| A new application of pre-normalized principal component analysis for improvement of image quality and clinical diagnosis in human brain PET studies--clinical brain studies using [11C]-GR205171, [11C]-L-deuterium-deprenyl, [11C]-5-Hydroxy-L-Tryptophan, [11C]-L-DOPA and Pittsburgh Compound-B. | NeuroImage 20061101 |
| Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. | Current drug targets 20061101 |
| Acute effects of moclobemide and deprenyl on 5-HT synthesis rates in the rat brain: An autoradiographic study. | Brain research bulletin 20061016 |
| Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy. | Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20061001 |
| A systematic review of research on strategies for the management of antipsychotic-induced sexual dysfunction: high-level evidence is needed. | The Journal of clinical psychiatry 20061001 |
| Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. | Parkinsonism & related disorders 20060901 |
| Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. | The Journal of clinical psychiatry 20060901 |
| The combined use of human neural and liver cell lines and mouse hepatocytes improves the predictability of the neurotoxicity of selected drugs. | Toxicology letters 20060820 |
| Cytoprotective effect of two synthetic enhancer substances, (-)-BPAP and (-)-deprenyl, on human brain capillary endothelial cells and rat PC12 cells. | Life sciences 20060808 |
| (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity. | European journal of pharmacology 20060807 |
| Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. | Journal of clinical pharmacology 20060801 |
| Effects of subchronic treatment with selegiline on L-DOPA-induced increase in extracellular dopamine level in rat striatum. | Journal of pharmacological sciences 20060801 |
| Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder. | Journal of child and adolescent psychopharmacology 20060801 |
| A new way to deliver psychiatric meds. | Behavioral healthcare 20060801 |
| Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy. | The Cochrane database of systematic reviews 20060719 |
| [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl]. | Orvosi hetilap 20060709 |
| L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. | Neurochemistry international 20060701 |
| Neuroprotective role of Bacopa monniera extract against aluminium-induced oxidative stress in the hippocampus of rat brain. | Neurotoxicology 20060701 |
| Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl. | Neurobiology of disease 20060701 |
| Transdermal selegiline: a novel MAOI formulation for depression. | Journal of psychosocial nursing and mental health services 20060701 |
| Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. | Journal of pharmacokinetics and pharmacodynamics 20060601 |
| High-throughput screening for monoamine oxidase-A and monoamine oxidase-B inhibitors using one-step fluorescence assay. | Acta pharmacologica Sinica 20060601 |
| Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. | Neurology 20060523 |
| Transdermal selegiline (Emsam). | The Medical letter on drugs and therapeutics 20060522 |
| Initial pharmacotherapy in a population of veterans with Parkinson disease. | Neurology 20060509 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Leading the way: advances in the diagnosis, treatment, and management of neuropsychiatric illnesses. | CNS spectrums 20060501 |
| Transdermal selegiline: the new generation of monoamine oxidase inhibitors. | CNS spectrums 20060501 |
| Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction on tyramine. | Journal of psychiatric practice 20060501 |
| Amphetamine-induced locomotor activity is reduced in mice following MPTP treatment but not following selegiline/MPTP treatment. | Pharmacology, biochemistry, and behavior 20060501 |
| High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users. | Journal of analytical toxicology 20060501 |
| The necessity of having a proper dose of (-)deprenyl (D) to prolong the life spans of rats explains discrepancies among different studies in the past. | Annals of the New York Academy of Sciences 20060501 |
| Selegiline slows the progression of the symptoms of Parkinson disease. | Neurology 20060425 |
| Patient page. Slowing down a 'slow' movement disorder: selegiline's benefit in treating Parkinson disease. | Neurology 20060425 |
| Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl]. | The Journal of pharmacology and experimental therapeutics 20060401 |
| Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression. | The Journal of clinical psychiatry 20060401 |
| Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats. | European journal of pharmacology 20060227 |
| The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development. | Journal of pharmaceutical and biomedical analysis 20060224 |
| Effects of selegiline on antioxidant systems in the nigrostriatum in rat. | Journal of neural transmission (Vienna, Austria : 1996) 20060201 |
| Modulation of brain mitochondrial function by deprenyl. | Neurochemistry international 20060201 |
| Clomipramine and selegiline: do they influence impulse control? | Journal of veterinary pharmacology and therapeutics 20060201 |
| H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice. | The European journal of neuroscience 20060201 |
| Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. | Biochemical and biophysical research communications 20060120 |
| Acute and delayed effect of (-) deprenyl and (-) 1-phenyl-2-propylaminopentane (PPAP) on the serotonin content of peritoneal cells (white blood cells and mast cells). | Cell biochemistry and function 20060101 |
| Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats. | Physiological research 20060101 |
| Chronic exposure of rats to cognition enhancing drugs produces a neuroplastic response identical to that obtained by complex environment rearing. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20060101 |
| Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane. | Progress in neuro-psychopharmacology & biological psychiatry 20060101 |
| A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys. | Psychopharmacology 20060101 |
| Efficacy and safety of high-dose cabergoline in Parkinson's disease. | Acta neurologica Scandinavica 20060101 |
| Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. | British journal of pharmacology 20060101 |
| Effect of nerodilol, carvone and anethole on the in vitro transdermal delivery of selegiline hydrochloride. | Die Pharmazie 20060101 |
| Treatment of primary progressive freezing of gait with high doses of selegiline. | Clinical neuropharmacology 20060101 |
| Persistent sexual side effects after SSRI discontinuation. | Psychotherapy and psychosomatics 20060101 |
| Quality of life in Parkinson's disease--Indian scenario. | The Journal of the Association of Physicians of India 20060101 |
| Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies. | The Journal of clinical psychiatry 20060101 |
| Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attrition. | The Journal of neuropsychiatry and clinical neurosciences 20060101 |
| First depression patch approved. | FDA consumer 20060101 |
| [Interaction of pyruvate kinase with isatin and deprenyl]. | Biomeditsinskaia khimiia 20060101 |
| Therapeutic options for cognitive decline in senior pets. | Journal of the American Animal Hospital Association 20060101 |
| Selegiline induces neuronal phenotype and neurotrophins expression in embryonic stem cells. | Rejuvenation research 20060101 |
| Isatin interaction with glyceraldehyde-3-phosphate dehydrogenase, a putative target of neuroprotective drugs: partial agonism with deprenyl. | Journal of neural transmission. Supplementum 20060101 |
| Deprenyl: from chemical synthesis to neuroprotection. | Journal of neural transmission. Supplementum 20060101 |
| Low dose (-)deprenyl is cytoprotective: it maintains mitochondrial membrane potential and eliminates oxygen radicals. | Life sciences 20051205 |
| A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. | Pharmacology, biochemistry, and behavior 20051201 |
| Dementia. | Clinical evidence 20051201 |
| Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons. | Brain research. Molecular brain research 20051130 |
| Deprenyl enhances the striatal neuronal damage produced by quinolinic acid. | Brain research. Molecular brain research 20051118 |
| Increased cell-cell adhesion, a novel effect of R-(-)-deprenyl. | Journal of neural transmission (Vienna, Austria : 1996) 20051101 |
| Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl. | Molecular pharmacology 20051101 |
| Selegiline protects against recognition memory impairment induced by neonatal iron treatment. | Experimental neurology 20051101 |
| Harmane inhibits serotonergic dorsal raphe neurons in the rat. | Psychopharmacology 20051101 |
| Parkinson's disease and sleep. | Neurologic clinics 20051101 |
| Selegiline orally disintegrating tablets for the treatment of Parkinson's disease. | Expert review of neurotherapeutics 20051101 |
| Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. | Expert review of neurotherapeutics 20051101 |
| Would caregivers of Alzheimer disease patients involve their relative in a decision to use an AD-slowing medication? | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20051101 |
| 2-Phenylethylamine in combination with l-deprenyl lowers the striatal level of dopamine and prolongs the duration of the stereotypy in mice. | Pharmacology, biochemistry, and behavior 20051101 |
| Effects of monoamine oxidase inhibitors on methamphetamine-induced stereotypy in mice and rats. | Neurochemical research 20051101 |
| Discriminative stimulus and reinforcing effects of p-fluoro-L-deprenyl in monkeys. | Psychopharmacology 20051001 |
| Antidepressant-like effects of selegiline in the forced swim test. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20051001 |
| In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20051001 |
| Protein aggregation in retinal cells and approaches to cell protection. | Cellular and molecular neurobiology 20050901 |
| Effects of selegiline alone or with donepezil on memory impairment in rats. | European journal of pharmacology 20050822 |
| LED fluorescence spectroscopy for direct determination of monoamine oxidase B inactivation. | Analytical biochemistry 20050815 |
| Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. | Journal of clinical pharmacology 20050801 |
| Reexamination of the TEMPO Study. | Archives of neurology 20050801 |
| Rasagiline. | Nature reviews. Drug discovery 20050801 |
| Monoamine oxidase B inhibitors for early Parkinson's disease. | The Cochrane database of systematic reviews 20050720 |
| Evidence for reduced arterial plasma input, prolonged lung retention and reduced lung monoamine oxidase in smokers. | Nuclear medicine and biology 20050701 |
| Detection of N-monomethyl-lysine generated by metabolic transmethylation. | Analytical and bioanalytical chemistry 20050601 |
| Contribution of L-3,4-dihydroxyphenylalanine metabolism to the inhibition of gluconeogenesis in rabbit kidney-cortex tubules. | The international journal of biochemistry & cell biology 20050601 |
| Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients. | Parkinsonism & related disorders 20050601 |
| Reversal of age-related deficits in object recognition memory in rats with l-deprenyl. | Experimental gerontology 20050601 |
| Parkinson's disease. | Clinical evidence 20050601 |
| Parkinson's disease. Diagnosis and the initiation of therapy. | Minerva medica 20050601 |
| Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. | Movement disorders : official journal of the Movement Disorder Society 20050501 |
| [A case of interval form of carbon monoxide poisoning with a remarkable recovery]. | Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20050501 |
| Mechanism of 1-methyl-4-phenylpyridinium-induced dopamine release from PC12 cells. | Neurochemical research 20050501 |
| HPLC and HPLC-MS analysis of urinary N(epsilon)-monomethyl-lysine. | Journal of chromatographic science 20050401 |
| [Role of R-(-)-deprenyl in adhesion of neuronal and non-neuronal cells]. | Orvosi hetilap 20050327 |
| 'Levodopa phobia': a new iatrogenic cause of disability in Parkinson disease. | Neurology 20050308 |
| Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. | Neuroscience research 20050301 |
| Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs. | Progress in neuro-psychopharmacology & biological psychiatry 20050301 |
| Estimation of endogenous noradrenaline release in rat brain in vivo using [3H]RX 821002. | Synapse (New York, N.Y.) 20050201 |
| The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients. | Acta neurologica Scandinavica 20050201 |
| Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. | The American journal of psychiatry 20050201 |
| Effects of high-dose selegiline on morphine reinforcement and precipitated withdrawal in dependent rats. | Behavioural pharmacology 20050201 |
| Selegiline in the management of apathy following traumatic brain injury. | Brain injury 20050201 |
| Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. | Neurology 20050111 |
| Selegiline modifies the extinction of responding following morphine self-administration, but does not alter cue-induced reinstatement, reacquisition of morphine reinforcement, or precipitated withdrawal. | Pharmacological research 20050101 |
| Molecular characterization of monoamine oxidase in zebrafish (Danio rerio). | Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 20050101 |
| Marked effect of liver and kidney function on the pharmacokinetics of selegiline. | Clinical pharmacology and therapeutics 20050101 |
| Intracellular dopamine oxidation mediates rotenone-induced apoptosis in PC12 cells. | Acta pharmacologica Sinica 20050101 |
| Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytriptamine turnover in the striatum. | Neuroscience 20050101 |
| sgk1, a member of an RNA cluster associated with cell death in a model of Parkinson's disease. | The European journal of neuroscience 20050101 |
| Other pharmacological treatments for motor complications and dyskinesias. | Movement disorders : official journal of the Movement Disorder Society 20050101 |
| Dislocation of the glenoid fossa. | Journal of shoulder and elbow surgery 20050101 |
| 'My involvement in aging research was just a series of coincidences' An interview with Kenichi Kitani. Interview by Sataro Goto. | Biogerontology 20050101 |
| Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report. | Clinical neuropharmacology 20050101 |
| A rapid, sensitive electron-capture gas chromatographic procedure for analysis of metabolites of N-methyl,N-propargylphenylethylamine, a potential neuroprotective agent. | Journal of pharmacological and toxicological methods 20050101 |
| Effect of I-deprenyl and gliclazide on oxidant stress/antioxidant status and dna damage in a diabetic rat model. | Endocrine research 20050101 |
| Dose-dependency of life span prolongation of F344/DuCrj rats injected with (-)deprenyl. | Biogerontology 20050101 |
| [Alzheimer's disease therapy--theory and practice]. | Wiadomosci lekarskie (Warsaw, Poland : 1960) 20050101 |
| Deprenyl, a therapeutic agent for Parkinson's disease, inhibits arsenic toxicity potentiated by GSH depletion via inhibition of JNK activation. | Journal of toxicology and environmental health. Part A 20041201 |
| Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease. | Medical science monitor : international medical journal of experimental and clinical research 20041201 |
| Treatment possibilities of Alzheimer's disease. | Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20041201 |
| The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression. | Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20041201 |
| Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. | Neurology 20041012 |
| A novel formulation of selegiline for the treatment of Parkinson's disease. | Neurology 20041012 |
| Clinical trials of neuroprotection for Parkinson's disease. | Neurology 20041012 |
| A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. | Neurology 20041012 |
| Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. | British journal of pharmacology 20041001 |
| Levodopa-responsive parkinsonism in hereditary spastic paraplegia with thin corpus callosum. | Parkinsonism & related disorders 20041001 |
| In vitro confirmation of selegiline N-oxidation by flavin-containing monooxygenase in rat microsome using LC-ESI MS. | Biological & pharmaceutical bulletin 20041001 |
| Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. | European journal of pharmacology 20040919 |
| Pitfalls of animal model systems in ageing research. | Best practice & research. Clinical endocrinology & metabolism 20040901 |
| Effects of repeated administration of Uncaria hooks on the acquisition and central neuronal activities in ethanol-treated mice. | Journal of ethnopharmacology 20040901 |
| (-)-Deprenyl alleviates the degenerative changes induced in the neonatal rat spinal cord by CSF from amyotrophic lateral sclerosis patients. | Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 20040901 |
| High-performance liquid chromatography/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridinium (MPP+) in brain tissue homogenates. | Journal of neuroscience methods 20040830 |
| 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B. | Neuroscience letters 20040826 |
| Subthalamic deep brain stimulation masking possible malignant syndrome in Parkinson disease. | Neurology 20040810 |
| Pharmacological aspects of (-)-deprenyl. | Current medicinal chemistry 20040801 |
| Assessment of the N-oxidation of deprenyl, methamphetamine, and amphetamine enantiomers by chiral capillary electrophoresis: an in vitro metabolism study. | Electrophoresis 20040801 |
| Selectivity of 7-alkoxycoumarins as probe substrates for rat hepatic cytochrome P450 forms is influenced by the substitution pattern on the coumarin nucleus. | Xenobiotica; the fate of foreign compounds in biological systems 20040801 |
| Selegiline potentiates the effects of EGb 761 in response to ischemic brain injury. | Neurochemistry international 20040701 |
| Selegiline, an MAO-B inhibitor, attenuates airway smooth muscle contraction in the rat trachea. | The Journal of pharmacy and pharmacology 20040701 |
| Selegiline increases heme oxygenase-1 expression and the cytotoxicity produced by dopamine treatment of neuroblastoma SK-N-SH cells. | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20040701 |
| Modulation of glucose uptake in glial and neuronal cell lines by selected neurological drugs. | Toxicology letters 20040615 |
| Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline. | Parkinsonism & related disorders 20040601 |
| Dementia. | Clinical evidence 20040601 |
| Parkinson's disease. | Clinical evidence 20040601 |
| 1-Benzyl-1,2,3,4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells. | Journal of neuroscience research 20040515 |
| Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives. | Progress in neuro-psychopharmacology & biological psychiatry 20040501 |
| Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Müller cells. | Investigative ophthalmology & visual science 20040501 |
| A 'cure' for Parkinson's disease: can neuroprotection be proven with current trial designs? | Movement disorders : official journal of the Movement Disorder Society 20040501 |
| Inefficacy of selegiline in treatment of canine pituitary-dependent hyperadrenocorticism. | Australian veterinary journal 20040501 |
| Comparison of the binding of the irreversible monoamine oxidase tracers, [(11)C]clorgyline and [(11)C]l-deprenyl in brain and peripheral organs in humans. | Nuclear medicine and biology 20040401 |
| Cardiopulmonary effects of medetomidine, oxymorphone, or butorphanol in selegiline-treated dogs. | Veterinary anaesthesia and analgesia 20040401 |
| Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. | Movement disorders : official journal of the Movement Disorder Society 20040401 |
| Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs. | Acta neuropathologica 20040301 |
| (-)-Deprenyl inhibits tyramine-induced noradrenaline release, but not tyramine-induced dopamine release or potassium-induced noradrenaline release, from rat brain synaptosomes. | Pharmacological research 20040301 |
| Transdermal selegiline and intravenous cocaine: safety and interactions. | Psychopharmacology 20040201 |
| l-Deprenyl prevents lipid peroxidation and memory deficits produced by cerebral ischemia in rats. | Cellular and molecular neurobiology 20040201 |
| Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. | Neuroscience letters 20040130 |
| Positive effects of deprenyl and estradiol on spatial memory and oxidant stress in aged female rat brains. | Neuroscience letters 20040116 |
| Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus. | Neurotoxicology 20040101 |
| (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. | Neurotoxicology 20040101 |
| Adverse effects of dopamine potentiation by long-term treatment with selegiline. | Movement disorders : official journal of the Movement Disorder Society 20040101 |
| Chiral separation of deprenyl-N-oxide isomers by capillary electrophoresis using various cyclodextrin derivatives. | Journal of chromatographic science 20040101 |
| [Prognosis in Alzheimer's disease]. | Nihon rinsho. Japanese journal of clinical medicine 20040101 |
| Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats. | Neurotoxicity research 20040101 |
| Brain cholinesterases: III. Future perspectives of AD research and clinical practice. | Medical hypotheses 20040101 |
| Effects of dopaminergic treatment on bladder function in Parkinson's disease. | Neurourology and urodynamics 20040101 |
| In vitro formation of selegiline-N-oxide as a metabolite of selegiline in human, hamster, mouse, rat, guinea-pig, rabbit and dog. | European journal of drug metabolism and pharmacokinetics 20040101 |
| [The effect of long-term administration of isatin and himantan to mice on sensitivity of brain monoamine oxidase B to inhibition by deprenyl in vivo and in vitro]. | Biomeditsinskaia khimiia 20040101 |
| Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial. | Journal of child and adolescent psychopharmacology 20040101 |
| Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTP-treated mice. | Journal of neural transmission (Vienna, Austria : 1996) 20031201 |
| Analysis of benzene ethylamine derivatives in urine using the programmable dynamic liquid-phase microextraction (LPME) device. | The Analyst 20031201 |
| The effects of chronic administration of inhibitors of flavin and quinone amine oxidases on imidazoline I(1) receptor density in rat whole brain. | Annals of the New York Academy of Sciences 20031201 |
| Relationship between imidazoline(2) sites and monoamine oxidase. | Annals of the New York Academy of Sciences 20031201 |
| Pro-apoptotic and anti-apoptotic molecules affecting pathways of signal transduction. | Annals of the New York Academy of Sciences 20031201 |
| Parkinson's disease. | Clinical evidence 20031201 |
| Reduced cardiovascular effects of methamphetamine following treatment with selegiline. | Drug and alcohol dependence 20031124 |
| Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity. | British journal of cancer 20031117 |
| Transdermal selegiline: targeted effects on monoamine oxidases in the brain. | Biological psychiatry 20031115 |
| L-Deprenyl as an inhibitor of menadione-induced permeability transition in liver mitochondria. | Biochemical pharmacology 20031101 |
| Clinical inquiries. What is the best initial treatment of Parkinson's disease? | The Journal of family practice 20031101 |
| Selegiline reduces N-methyl-D-aspartic acid induced perturbation of neurotransmission but it leaves NMDA receptor dependent long-term potentiation intact in the hippocampus. | Journal of neural transmission (Vienna, Austria : 1996) 20031101 |
| A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. | Journal of neural transmission (Vienna, Austria : 1996) 20031101 |
| A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. | Journal of neural transmission (Vienna, Austria : 1996) 20031101 |
| Selegiline's neuroprotective capacity revisited. | Journal of neural transmission (Vienna, Austria : 1996) 20031101 |
| L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment. | Neurology 20031014 |
| D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity. | Synapse (New York, N.Y.) 20031001 |
| A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. | Addiction (Abingdon, England) 20031001 |
| Pharmacologic treatment of Alzheimer's disease: an update. | American family physician 20031001 |
| Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects. | Prescrire international 20031001 |
| L-selegiline potentiates the cellular poly(ADP-ribosyl)ation response to ionizing radiation. | The Journal of pharmacology and experimental therapeutics 20030901 |
| Selegiline long-term effects on brain acetylcholinesterase, (Na+,K+)-ATPase activities, antioxidant status and learning performance of aged rats. | Pharmacological research 20030901 |
| Cytochrome P450-dependent metabolism of l-deprenyl in monkey (Cercopithecus aethiops) and C57BL/6 mouse brain microsomal preparations. | Journal of neurochemistry 20030901 |
| Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. | Drug metabolism and disposition: the biological fate of chemicals 20030901 |
| Deprenyl blocks the aglycemia-induced depression of the synaptic transmission but not the ischemia-induced depression in neonatal rat spinal cord in vitro. | Neuroscience research 20030901 |
| Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. | Neurology 20030812 |
| [Therapy for patients with early-stage Parkinson's disease]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20030810 |
| Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives. | Neurochemical research 20030801 |
| Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture. | Neuroscience research 20030801 |
| Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice. | Journal of neural transmission (Vienna, Austria : 1996) 20030801 |
| Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate. | Journal of neural transmission (Vienna, Austria : 1996) 20030801 |
| Chiral characterization of deprenyl-N-oxide and other deprenyl metabolites by capillary electrophoresis using a dual cyclodextrin system in rat urine. | Electrophoresis 20030801 |
| Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. | Progress in neuro-psychopharmacology & biological psychiatry 20030801 |
| Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats. | Brain research 20030627 |
| Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons. | Antioxidants & redox signaling 20030601 |
| An HPLC tracing of the enhancer regulation in selected discrete brain areas of food-deprived rats. | Life sciences 20030509 |
| Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes. | Life sciences 20030502 |
| Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. | Journal of neural transmission (Vienna, Austria : 1996) 20030501 |
| Environmental influence on recovery after brain lesions--experimental and clinical data. | Journal of rehabilitation medicine 20030501 |
| Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons. | Journal of neurocytology 20030501 |
| A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study. | Life sciences 20030425 |
| Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine. | Synapse (New York, N.Y.) 20030401 |
| Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication. | Journal of analytical toxicology 20030401 |
| Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension. | Parkinsonism & related disorders 20030301 |
| Safety of selegiline with cold medications. | The Annals of pharmacotherapy 20030301 |
| [Biomedical imaging in pharmacology with nuclear medical imaging methodologies: positron emission tomography (PET) and single photon emission computed tomography (SPECT)]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20030301 |
| Monoamine oxidase inhibitors--is it time to up the TEMPO? | The Lancet. Neurology 20030301 |
| Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: association with improvement of cardiac function. | European journal of pharmacology 20030214 |
| l-Deprenyl metabolism by the cytochrome P450 system in monkey (Cercopithecus aethiops) liver microsomes. | Xenobiotica; the fate of foreign compounds in biological systems 20030201 |
| A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. | The Journal of clinical psychiatry 20030201 |
| The relevance of preclinical studies for the treatment of Parkinson's disease. | Journal of neurology 20030201 |
| A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. | Biological psychiatry 20030115 |
| Protective effects of selegiline and desmethylselegiline against N-methyl-D-aspartate-induced rat retinal damage. | European journal of pharmacology 20030101 |
| Evidence for dopamine-derived hydroxyl radical formation in the nigrostriatal system in response to axotomy. | Free radical biology & medicine 20030101 |
| Selegiline for Alzheimer's disease. | The Cochrane database of systematic reviews 20030101 |
| In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography. | Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20030101 |
| Selegiline-transdermal--Somerset: Emsam. | Drugs in R&D 20030101 |
| Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion. | Neurobiology of aging 20030101 |
| Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. | The Journal of pharmacy and pharmacology 20030101 |
| Neuroprotection for Parkinson's disease: prospects and promises. | Annals of neurology 20030101 |
| Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease. | Dementia and geriatric cognitive disorders 20030101 |
| Neurostimulatory and antioxidative effects of L-deprenyl in aged rat brain regions. | Biogerontology 20030101 |
| Clinical pharmacokinetics of cabergoline. | Clinical pharmacokinetics 20030101 |
| Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study. | Clinical neuropharmacology 20030101 |
| Noncholinergic treatment options for Alzheimer's disease. | The Journal of clinical psychiatry 20030101 |
| Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease. | Journal of neural transmission. Supplementum 20030101 |
| Antioxidant properties of newly synthesized N-propargylamine derivatives of nitroxyl: a comparison with deprenyl. | Polish journal of pharmacology 20030101 |
| Neuroprotective effect of deprenyl in sensory neurons of axotomized dorsal root ganglion. | Clinical neuropharmacology 20030101 |
| [Mild cognitive impairment]. | Ryoikibetsu shokogun shirizu 20030101 |
| [Effect of a new antiparkinsonian drug himantane on monoamine oxidase activity]. | Eksperimental'naia i klinicheskaia farmakologiia 20030101 |
| Medical treatment of hyperadrenocorticism in the dog. | Australian veterinary journal 20030101 |
| Detection, quantification, metabolism, and behavioral effects of selegiline in horses. | Veterinary therapeutics : research in applied veterinary medicine 20030101 |
| Selegiline enhances erectile activity induced by dopamine injection in the paraventricular nucleus of the hypothalamus in anesthetized rats. | International journal of impotence research 20021201 |
| [Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100): outcome of 5-year treatment]. | No to shinkei = Brain and nerve 20021201 |
| Recent advances in Parkinson's disease. | Ideggyogyaszati szemle 20021120 |
| Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. | The American journal of psychiatry 20021101 |
| Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. | Neuropharmacology 20021101 |
| Effects of short- and long-term (--)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain. | Brain research 20021025 |
| PET imaging of monoamine oxidase B in peripheral organs in humans. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20021001 |
| Quantitative analysis of selegiline and three metabolites (N-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. | Journal of analytical toxicology 20021001 |
| Practical importance of neuroprotection in Parkinson's disease. | Journal of neurology 20021001 |
| 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged. | Life sciences 20020913 |
| Effects of selegiline (L-deprenyl) during smoking and short-term abstinence. | Psychopharmacology 20020901 |
| Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man. | Xenobiotica; the fate of foreign compounds in biological systems 20020901 |
| Selegiline: a second look. Six years later: too risky in Parkinson's disease. | Prescrire international 20020801 |
| Selegiline transdermal system Somerset. | Current opinion in investigational drugs (London, England : 2000) 20020801 |
| Effects of (-)deprenyl (selegiline) on acetylcholinesterase and Na(+),K(+)-ATPase activities in adult rat whole brain. | Pharmacological research 20020801 |
| Treatment of an acromegalic cat with the dopamine agonist L-deprenyl. | Australian veterinary journal 20020801 |
| [The usefulness of dopaminergic drugs in traumatic brain injury]. | Revista de neurologia 20020801 |
| Neurological effects of psychopharmacological agents. | Seminars in clinical neuropsychiatry 20020701 |
| Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline. | European journal of clinical pharmacology 20020701 |
| Smoking cessation and panic attacks: a report of 2 cases. | The Journal of clinical psychiatry 20020701 |
| Electroencephalographic activation by tacrine, deprenyl, and quipazine: cholinergic vs. non-cholinergic contributions. | European journal of pharmacology 20020628 |
| Effects of selegiline, phenylpropanolamine, or a combination of both on physiologic and behavioral variables in healthy dogs. | American journal of veterinary research 20020601 |
| Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. | Journal of occupational and environmental medicine 20020501 |
| (-)-Deprenyl fails to promote axonal regeneration of retinal ganglion cells in vitro and in vivo. | Cell and tissue research 20020501 |
| The effect of deprenyl washout in patients with long-standing Parkinson's disease. | Journal of neural transmission (Vienna, Austria : 1996) 20020501 |
| Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. | Annals of neurology 20020501 |
| Modulation of neuroendocrine--immune signaling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer. | Mechanisms of ageing and development 20020430 |
| Why (--)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. | Mechanisms of ageing and development 20020430 |
| Pharmacological interventions in aging and age-associated disorders: potentials of propargylamines for human use. | Annals of the New York Academy of Sciences 20020401 |
| Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation. | International journal of geriatric psychiatry 20020401 |
| [Serotonin syndrome: report of a fatal case and review of the literature]. | Revista clinica espanola 20020401 |
| [The evolution of use of anti-Parkinson drugs in Spain]. | Revista de neurologia 20020401 |
| Inhibition of human LDL oxidation by the neuroprotective drug l-deprenyl. | Neurological research 20020301 |
| Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20020301 |
| Treatment of periodic limb movements in sleep with selegiline HCl. | Movement disorders : official journal of the Movement Disorder Society 20020301 |
| Effect of R-(-)-deprenyl and harmaline on dopamine- and peroxynitrite-induced membrane permeability transition in brain mitochondria. | Neurochemical research 20020301 |
| Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. | Parkinsonism & related disorders 20020301 |
| Neuroprotective actions of selegiline. | Journal of neuroscience research 20020201 |
| The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. | International journal of geriatric psychiatry 20020201 |
| Antiapoptotic effect of (-)-deprenyl in rat kidney after ischemia-reperfusion. | Medical science monitor : international medical journal of experimental and clinical research 20020201 |
| Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum. | Toxicology 20020125 |
| The influence of metabolism on the MAO-B inhibitory potency of selegiline. | Current medicinal chemistry 20020101 |
| Effect of repeated treatment with high doses of selegiline on behaviour, striatal dopaminergic transmission and tyrosine hydroxylase mRNA levels. | Naunyn-Schmiedeberg's archives of pharmacology 20020101 |
| Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice. | Methods and findings in experimental and clinical pharmacology 20020101 |
| Morphometric evaluation of the neuroprotective effect of deprenyl on postaxotomic motor neuron losses. | Clinical neuropharmacology 20020101 |
| [Study of the tissue and subcellular distribution of isatin-binding proteins with optical biosensor]. | Voprosy meditsinskoi khimii 20020101 |
| Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline. | Clinical neuropharmacology 20020101 |
| MAO-B inhibitors for the treatment of Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20020101 |
| [Monoamine oxidase inhibitors: prospects for the use in clinical practice]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20020101 |
| The multiple actions of selegiline. | Proceedings of the Western Pharmacology Society 20020101 |
| Monoamine oxidase inhibitors: a new generation. | Psychopharmacology bulletin 20020101 |
| Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy. | The Cochrane database of systematic reviews 20020101 |
| [Effectiveness and tolerability of selegiline in the treatment of pathological cerebral involutions]. | La Clinica terapeutica 20020101 |
| Zonisamide has beneficial effects on Parkinson's disease patients. | Neuroscience research 20011201 |
| Investigating potential anxiolytic, antidepressant and memory enhancing activity of deprenyl. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20011201 |
| Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. | Neurology 20011113 |
| Chronic daily administration of selegiline and EGb 761 increases brain's resistance to ischemia in mice. | Brain research 20011102 |
| (-)-D-Deprenyl attenuates apoptosis in experimental brain ischaemia. | European journal of pharmacology 20011102 |
| CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. | Drug metabolism and disposition: the biological fate of chemicals 20011101 |
| The effects of oral selegiline hydrochloride on learning and training in the dog: a psychobiological interpretation. | Progress in neuro-psychopharmacology & biological psychiatry 20011101 |
| Role of monoamine oxidase inhibition and monoamine depletion in fenfluramine-induced neurotoxicity and serotonin release. | Pharmacology & toxicology 20011101 |
| Future of neuroprotection in Parkinson's disease. | Parkinsonism & related disorders 20011001 |
| Incorporation of selegiline metabolites into hair after oral selegiline intake. | Journal of analytical toxicology 20011001 |
| Medical treatment of canine pituitary-dependent hyperadrenocorticism (Cushing's disease). | The Veterinary clinics of North America. Small animal practice 20010901 |
| Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry. | Journal of chromatography. B, Biomedical sciences and applications 20010805 |
| Inhibition of rat liver microsomal CYP1A2 and CYP2B1 activity by N-(2-heptyl)-N-methyl-propargylamine and by N-(2-heptyl)-propargylamine. | Drug metabolism and disposition: the biological fate of chemicals 20010801 |
| [Parkinson's disease]. | Nihon rinsho. Japanese journal of clinical medicine 20010801 |
| Changes in vascular alpha 1- and alpha 2-adrenoceptor responsiveness by selegiline treatment. | Fundamental & clinical pharmacology 20010801 |
| Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. | Neurology 20010724 |
| Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. | Neurology 20010724 |
| Current advances in Parkinson's disease. | Trends in neurosciences 20010701 |
| Freezing of gait in PD: prospective assessment in the DATATOP cohort. | Neurology 20010626 |
| Oxygen inhalation enhances striatal dopamine metabolism and monoamineoxidase enzyme inhibition prevents it: a microdialysis study. | European journal of pharmacology 20010622 |
| Advances in managing Parkinson's disease. | Hospital practice (1995) 20010615 |
| PET with 11C-deuterium-deprenyl and 18F-FDG in focal epilepsy. | Acta neurologica Scandinavica 20010601 |
| The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome. | Neurobiology of disease 20010601 |
| Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks. | Pharmacology & toxicology 20010601 |
| Rescue of dying neurons by (R)-deprenyl in the MPTP-mouse model of Parkinson's disease does not include restoration of neostriatal dopamine. | Annals of the New York Academy of Sciences 20010601 |
| Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease. | Journal of neurology 20010601 |
| [Parkinson patients. Normal life expectancy with selegiline?]. | MMW Fortschritte der Medizin 20010528 |
| Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. | Life sciences 20010504 |
| Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. | Bioorganic & medicinal chemistry 20010501 |
| CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. | European journal of clinical pharmacology 20010501 |
| Monoamine oxidase assays. | Current protocols in pharmacology 20010501 |
| L-Deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP(+) and beta-carbolinium: a microdialysis study in rats. | Neuroscience letters 20010420 |
| Selective inhibition of MAO-B through chronic low-dose (R)-deprenyl treatment in C57BL/6 mice has no effect on basal neostriatal dopamine levels. | Experimental neurology 20010401 |
| Attenuation of paraquat-induced dopaminergic toxicity on the substantia nigra by (-)-deprenyl in vivo. | Toxicology and applied pharmacology 20010401 |
| Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. | European journal of clinical pharmacology 20010401 |
| Deprenyl stimulates the efflux of monoamines from the rat hypothalamus in vitro. | Brain research bulletin 20010401 |
| Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy. | Annals of the New York Academy of Sciences 20010401 |
| Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid. | The Journal of biological chemistry 20010330 |
| L-dopa and selegiline for tyrosine hydroxylase deficiency. | The Journal of pediatrics 20010301 |
| Parkinson's disease therapy: treatment of early and late disease. | Chinese medical journal 20010301 |
| Eldepryl prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral neuronal apoptosis in mice. | Chinese medical journal 20010301 |
| SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. | Brain research 20010223 |
| Selective inhibition of amine oxidases differently potentiate the hypophagic effect of benzylamine in mice. | European journal of pharmacology 20010209 |
| Selegiline combined with enriched-environment housing attenuates spatial learning deficits following focal cerebral ischemia in rats. | Experimental neurology 20010201 |
| The economic consequences of a drug-drug interaction. | Journal of clinical psychopharmacology 20010201 |
| Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. | Acta neuropathologica 20010201 |
| Possible applications for dopaminergic agents following traumatic brain injury: part 2. | The Journal of head trauma rehabilitation 20010201 |
| Selegiline completely restores choline acetyltransferase activity deficits in simian immunodeficiency infection. | European journal of pharmacology 20010105 |
| Different sensitivity of mitochondrial and cytosolic monoamine oxidases to in vivo but not in vitro inhibition by specific irreversible inhibitors. | Medical science monitor : international medical journal of experimental and clinical research 20010101 |
| Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites. | Journal of neural transmission (Vienna, Austria : 1996) 20010101 |
| Freezing of gait in patients with advanced Parkinson's disease. | Journal of neural transmission (Vienna, Austria : 1996) 20010101 |
| Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study. | Journal of neural transmission (Vienna, Austria : 1996) 20010101 |
| Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion. | Neurochemical research 20010101 |
| [Current strategies of pathogenetic therapy of Alzheimer's disease]. | Vestnik Rossiiskoi akademii meditsinskikh nauk 20010101 |
| Effect of longevity treatment with (-)deprenyl on lifespan and sexual behavior in female rats. | Neurobiology (Budapest, Hungary) 20010101 |
| Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain. | CNS drug reviews 20010101 |
| Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. | Journal of neural transmission (Vienna, Austria : 1996) 20010101 |
| [The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trials]. | Neurologia i neurochirurgia polska 20010101 |
| The effect of low oral doses of (-)-deprenyl and its metabolites on DSP-4 toxicity. | Journal of neural transmission (Vienna, Austria : 1996) 20010101 |
| Pharmacological options for the treatment of Tourette's disorder. | Drugs 20010101 |
| Selegiline treatment facilitates recovery after stroke. | Neurorehabilitation and neural repair 20010101 |
| A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting. | Veterinary therapeutics : research in applied veterinary medicine 20010101 |
| [Dopaminergic agonists in the treatment of Parkinson's disease]. | Revue medicale de Bruxelles 20001201 |
| Antioxidant activity of the monoamine oxidase B inhibitor lazabemide. | Biochemical pharmacology 20000901 |
| A hypertensive reaction induced by concurrent use of selegiline and dopamine. | The Annals of pharmacotherapy 20000901 |
| Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. | Clinical neuropharmacology 20000101 |
| The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats. | Journal of neural transmission (Vienna, Austria : 1996) 20000101 |
| Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine. | European psychiatry : the journal of the Association of European Psychiatrists 19991001 |
| Effect of selegiline on cognitive functions in Parkinson's disease. | The Journal of the Association of Physicians of India 19990801 |
| Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 19990601 |
| Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal. | Movement disorders : official journal of the Movement Disorder Society 19990301 |
| Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). | Journal of neural transmission. Supplementum 19980101 |
| Experience with tranylcypromine in early Parkinson's disease. | Journal of neural transmission. Supplementum 19980101 |
| Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. | Journal of neurology, neurosurgery, and psychiatry 19970801 |
| The anticonvulsant effect of deprenyl on pentylenetetrazol-induced seizures in Lewis rats. | The International journal of neuroscience 19970801 |
| Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome. | Journal of clinical psychopharmacology 19970201 |
| Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. | Drug and alcohol dependence 19950701 |
| Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. | Clinical pharmacology and therapeutics 19941201 |
| The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine. | Brain research 19940711 |
| Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327. | Neurology 19931001 |
| End-of-dose dystonia in Parkinson's disease. | Neurology 19931001 |
| Deprenyl in attention deficit associated with Tourette's syndrome. | Archives of neurology 19930301 |
| Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline. | Lancet (London, England) 19930227 |
| Selegiline and manic behavior in Parkinson's disease. | Archives of neurology 19921201 |
| In vivo and in vitro pharmacologic profile of two new irreversible MAO-B inhibitors: MDL 72,974A and fluorodeprenyl. | Annals of the New York Academy of Sciences 19920511 |
| Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. | Neurology 19920301 |
| Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. | The Journal of pharmacology and experimental therapeutics 19911101 |
| Improvement of cognitive function by MAO-B inhibitor L-deprenyl in aged rats. | Pharmacology, biochemistry, and behavior 19910601 |
| A review of the pharmacology of selegiline. | Acta neurologica Scandinavica. Supplementum 19910101 |
| Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage. | International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 19910101 |
| Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans. | Advances in neurology 19900101 |
| The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. | Science (New York, N.Y.) 19890804 |
| A possible L-deprenyl induced hypertensive reaction. | Journal of clinical psychopharmacology 19890801 |
| Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase. | Journal of neural transmission 19870101 |
| SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents. | The Journal of pharmacology and experimental therapeutics 19870101 |
| Pharmacokinetic aspects of deprenyl effects. | Polish journal of pharmacology and pharmacy 19840101 |
| Brain monoamine oxidase in suckling rabbits treated with organophosphorus compound. I. Acute intoxication. | Acta physiologica Polonica 19840101 |
| Deprenyl (selegiline) in combination treatment of Parkinson's disease. | Acta neurologica Scandinavica. Supplementum 19830101 |
| The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. | Biochemical pharmacology 19821115 |
| Inhibition of rabbit liver monoamine oxidase by nitro aromatic compounds. | Biochemical pharmacology 19820815 |
| Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl. | Clinical and experimental neurology 19790101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.